Final answer:
COX-2 inhibitors are generally designed to decrease GIT symptoms and do not affect platelet function, but they are not considered safe in asthma and can affect renal function.
Step-by-step explanation:
The incorrect statement among the options provided regarding COX-2 inhibitors is: C. Safe in asthma. While COX-2 inhibitors, such as celecoxib, are indeed designed to decrease gastrointestinal symptoms associated with non-selective NSAIDs, suggesting they should decrease GIT symptoms (Option A), they can still have noteworthy effects on other systems. These drugs have no effect on platelet function (Option B), because platelets express mainly COX-1, which is less affected by COX-2 selective inhibitors. However, they are not necessarily safe in individuals with asthma, as NSAIDs can provoke bronchospasm in susceptible individuals, particularly those with aspirin-exacerbated respiratory disease.
Regarding Option D, it is also incorrect to state that COX-2 inhibitors have no effect on renal function. Like non-selective NSAIDs, COX-2 selective inhibitors may impair renal function in certain vulnerable populations or those with preexisting renal issues due to their role in kidney homeostasis. Regular monitoring and cautious use are recommended to prevent potential renal complications.